Q2 2025 Sangamo Therapeutics Inc Earnings Call Transcript

Aug 7, 2025 / 08:30 PM GMT

Release Date Price: $0.5044 (-1.70%)

Transcript 10-Q8-K

Key Points

Positve

Sangamo Therapeutics Inc (SGMO) announced positive top-line results from their Fabry disease study, showing a positive mean annualized EGFR slope at 52 weeks, which the FDA has agreed will serve as a primary basis for accelerated approval.
The company has initiated its first clinical site for a neurology genomic medicine program, marking its entry into clinical-stage neurology genomic medicine.
Sangamo Therapeutics Inc (SGMO) held a productive meeting with the UK's MHRA for their prion disease program, aligning on planned non-clinical safety studies and clinical study design.
The company completed an equity offering to support its operations, with a cash runway expected to fund planned operations into the fourth quarter of 2025.
Sangamo Therapeutics Inc (SGMO) is actively engaging in business development negotiations for a potential Fabry commercialization agreement and broader business development discussions across its pipeline and platforms.

Negative

Sangamo Therapeutics Inc (SGMO) faces challenges in securing adequate additional funding to support its long-term operations and pipeline advancements.
The company has not yet held its pre-BLA meeting with the FDA, which is crucial for finalizing the path to approval for its Fabry disease treatment.
There is uncertainty regarding the adoption rate of their Fabry disease treatment, as surveys with patients and physicians have not been explicitly mentioned.
Sangamo Therapeutics Inc (SGMO) is operating in a challenging environment, which may impact its ability to advance its pipeline and secure partnerships.
The company's current cash runway only extends into the fourth quarter of 2025, highlighting the urgency to secure a commercialization partner and additional funding.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

SGMO.OQ - Sangamo Therapeutics Inc
Q2 2025 Sangamo Therapeutics Inc Earnings Call
Aug 07, 2025 / 08:30PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Good afternoon and welcome to the Sangamo Therapeutic 2nd quarter 2025 teleconference call. Please be advised that today's conference is being recorded. I would now like to turn the conference over to your speaker today, Louise Wilke, head of investor relations and corporate communications. Please go ahead.

--------------------------------------------------------------------------------
Unidentified_2 [2]
--------------------------------------------------------------------------------
Thank you. Good afternoon, everyone.

Thank you for joining us on the call today. On this call are several members of the Sanoma executive leadership team, including Sandy McCray, Chief Executive Officer, Natalie

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.